What’s New in the European ACS Guidelines and How Will My Practice Change?
Published: 05 October 2023
-
Views:
16609
-
Likes:
7
-
Views:
16609
-
Likes:
7
-
Up Next
-
6m 51sPart 2 Introduction
-
32m 31sPart 3 Early Treatment
-
29m 13sPart 4 Long-Term Treatment
-
19m 42s
Overview
Led by Prof Robert Storey (University of Sheffield, Sheffield, UK), this on-demand version of the live broadcast delves into the 2023 ACS guideline updates that were recently presented at the European Society of Cardiology (ESC) annual meeting in Amsterdam.
Join the conversation with Dr Dominick Angiolillo (University of Florida, Gainesville, US), Dr Christopher Cannon (Brigham and Women's Hospital, Boston, US), Prof Pascal Vranckx (Heart Centre Hasselt, Hasselt, BE) and Prof Stefan James (Uppsala University, Uppsala, SE) as they discuss the new recommendations, offering valuable insights for their integration into daily practice. Gain a comprehensive understanding as they compare these guidelines with others, including those from American societies.
Key Learning Objectives
- Summarise major updates to European guidance on the use of antithrombotic agents in ACS patients
- Recall clinical evidence underlining recent updates to European guidance on the use of antithrombotic agents
- Compare the recent European guidance for the treatment of ACS with other existing guidance
- Apply new recommendations around the use of antithrombotic agents in daily practice
Target Audience
- Cardiologists
- Interventional Cardiologists
- Primary Care Physicians
- Nurses, Pharmacists
- Other Applied HCPs
More from this programme
Part 1
Summary
Part 2
Introduction
Prof Storey provides a brief overview of the 2023 ACS guidelines and expert consensus documents. Following this, the audience vote on the first polls, capturing real-time insights into the current utilisation of P2Y12 inhibitors in their practices.
| 1 session | |
| Introduction | Watch now |
Part 3
Early Treatment
Prof Storey presents the ESC 2023 guideline recommendations on antiplatelet therapy including pretreatment. Dr Angiolillo presents compelling evidence on the hot topic of pretreatment versus no pretreatment in NSTEACS.
The panel then engage in discussion, sharing their personal approaches to pretreatment. Dr Cannon provides a comparative analysis between ESC and US guidelines on pretreatment, as the panel explores the clinical data gaps that challenge decision-making in this critical arena.
| 1 session | |
| Early Treatment | Watch now |
Part 4
Long-Term Treatment
Prof Storey provides an update on new recommendations on antiplatelet use post-PCI, drawing on data from several pivotal trials and meta-analyses that provide the rationale for these recommendations.
The panel then focus on new recommendations around "alternative" antithrombotic regimens in high-risk patients and discuss the practicalities of shortening DAPT in the real-world.
| 1 session | |
| Long-Term Treatment | Watch now |
Part 5
Your Clinical Questions Answered
The expert panel respond to clinical questions from the audience which sparks a fascinating conversation, enriching the understanding of complex issues in the field.
| 1 session | |
| Your Clinical Questions Answered | Watch now |
Faculty Biographies
Robert F Storey
Professor and Honorary Consultant in Cardiology
Prof Robert Storey is Academic Director and an honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust. He is Professor of Cardiology at the University of Sheffield, UK, where he has headed a platelet research group since 2002 within the Department of Cardiovascular Science.
He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention. He served as a member of the executive committees for the PLATO and PEGASUS studies, leading the platelet function substudies for these trials, and of the steering committee for the TRA-CER, EPICOR and ATLANTIC studies. He is currently a member of the steering committee for the COMPLETE study. He was Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC) from 2012-2014 and has been a Task Force member for several ESC guidelines on non-ST-elevation acute…
Dominick J Angiolillo
Professor & Chief
Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. Dr Angiolillo is board-certified in internal medicine, cardiovascular disease and interventional cardiology.
In 2004, Dr Angiolillo joined the University of Florida College of Medicine in Jacksonville, where he is a professor of medicine, director of cardiovascular research and director of the interventional cardiology fellowship program.
Dr Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his…
Christopher P Cannon
Professor
Dr Christopher Cannon is a Professor of Medicine at Harvard Medical School, and Senior Physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital.
He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.
Dr Cannon has published over 1000 original articles, reviews or book chapters in the field of acute coronary syndromes and prevention and has authored or edited 18 books. He has received numerous awards, including leadership awards from the American College of Cardiology, American Heart Association and National Lipid Association.
He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI and VERTIS CV trials.
Dr Cannon is on the…
Pascal Vranckx
Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services
Prof Pascal Vranckx is a Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services at the Hartcentrum Hasselt in Belgium, and Professor of Medicine at the University of Hasselt, Belgium.
Prof Vranckx is also board member of the European Cardiovascular Research Institute, in Rotterdam, The Netherlands.
Stefan James
Professor of Cardiology
Prof Stefan James is Professor of Cardiology at Uppsala University, Scientific Director of Uppsala Clinical Research Center and a senior Interventional Cardiologist at Uppsala University Hospital in Sweden. He is the president of the Swedish society of Cardiology and a Fellow of the ESC.
He graduated from Uppsala University Medical School and completed specialist training in Uppsala. He has previously held positions at the Karolinska Hospital, the University Hospital Örebro and Duke Clinical Research Institute, Duke University.
Comments